1016 related articles for article (PubMed ID: 21147047)
1. Deconstructing the molecular portraits of breast cancer.
Prat A; Perou CM
Mol Oncol; 2011 Feb; 5(1):5-23. PubMed ID: 21147047
[TBL] [Abstract][Full Text] [Related]
2. Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer.
Prat A; Parker JS; Karginova O; Fan C; Livasy C; Herschkowitz JI; He X; Perou CM
Breast Cancer Res; 2010; 12(5):R68. PubMed ID: 20813035
[TBL] [Abstract][Full Text] [Related]
3. Clinical implications of the intrinsic molecular subtypes of breast cancer.
Prat A; Pineda E; Adamo B; Galván P; Fernández A; Gaba L; Díez M; Viladot M; Arance A; Muñoz M
Breast; 2015 Nov; 24 Suppl 2():S26-35. PubMed ID: 26253814
[TBL] [Abstract][Full Text] [Related]
4. Genomic subtypes of breast cancer identified by array-comparative genomic hybridization display distinct molecular and clinical characteristics.
Jönsson G; Staaf J; Vallon-Christersson J; Ringnér M; Holm K; Hegardt C; Gunnarsson H; Fagerholm R; Strand C; Agnarsson BA; Kilpivaara O; Luts L; Heikkilä P; Aittomäki K; Blomqvist C; Loman N; Malmström P; Olsson H; Johannsson OT; Arason A; Nevanlinna H; Barkardottir RB; Borg A
Breast Cancer Res; 2010; 12(3):R42. PubMed ID: 20576095
[TBL] [Abstract][Full Text] [Related]
5. Molecular biology in breast cancer: intrinsic subtypes and signaling pathways.
Eroles P; Bosch A; Pérez-Fidalgo JA; Lluch A
Cancer Treat Rev; 2012 Oct; 38(6):698-707. PubMed ID: 22178455
[TBL] [Abstract][Full Text] [Related]
6. Re-definition of claudin-low as a breast cancer phenotype.
Fougner C; Bergholtz H; Norum JH; Sørlie T
Nat Commun; 2020 Apr; 11(1):1787. PubMed ID: 32286297
[TBL] [Abstract][Full Text] [Related]
7. Molecular classification of breast carcinomas with particular emphasis on "basal-like" carcinoma: a critical review.
Lavasani MA; Moinfar F
J Biophotonics; 2012 Apr; 5(4):345-66. PubMed ID: 22232077
[TBL] [Abstract][Full Text] [Related]
8. Normal Breast-Derived Epithelial Cells with Luminal and Intrinsic Subtype-Enriched Gene Expression Document Interindividual Differences in Their Differentiation Cascade.
Kumar B; Prasad M; Bhat-Nakshatri P; Anjanappa M; Kalra M; Marino N; Storniolo AM; Rao X; Liu S; Wan J; Liu Y; Nakshatri H
Cancer Res; 2018 Sep; 78(17):5107-5123. PubMed ID: 29997232
[TBL] [Abstract][Full Text] [Related]
9. Immunohistochemical features of claudin-low intrinsic subtype in metaplastic breast carcinomas.
Gerhard R; Ricardo S; Albergaria A; Gomes M; Silva AR; Logullo ÂF; Cameselle-Teijeiro JF; Paredes J; Schmitt F
Breast; 2012 Jun; 21(3):354-60. PubMed ID: 22464177
[TBL] [Abstract][Full Text] [Related]
10. Molecular profiling of breast cancer cell lines defines relevant tumor models and provides a resource for cancer gene discovery.
Kao J; Salari K; Bocanegra M; Choi YL; Girard L; Gandhi J; Kwei KA; Hernandez-Boussard T; Wang P; Gazdar AF; Minna JD; Pollack JR
PLoS One; 2009 Jul; 4(7):e6146. PubMed ID: 19582160
[TBL] [Abstract][Full Text] [Related]
11. Expression and methylation patterns partition luminal-A breast tumors into distinct prognostic subgroups.
Netanely D; Avraham A; Ben-Baruch A; Evron E; Shamir R
Breast Cancer Res; 2016 Jul; 18(1):74. PubMed ID: 27386846
[TBL] [Abstract][Full Text] [Related]
12. Claudin expression in breast cancer: high or low, what to expect?
Ricardo S; Gerhard R; Cameselle-Teijeiro JF; Schmitt F; Paredes J
Histol Histopathol; 2012 Oct; 27(10):1283-95. PubMed ID: 22936447
[TBL] [Abstract][Full Text] [Related]
13. Nonfamilial breast cancer subtypes.
Ringnér M; Staaf J; Jönsson G
Methods Mol Biol; 2013; 973():279-95. PubMed ID: 23412797
[TBL] [Abstract][Full Text] [Related]
14. HER2-enriched subtype as a predictor of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer (PAMELA): an open-label, single-group, multicentre, phase 2 trial.
Llombart-Cussac A; Cortés J; Paré L; Galván P; Bermejo B; Martínez N; Vidal M; Pernas S; López R; Muñoz M; Nuciforo P; Morales S; Oliveira M; de la Peña L; Peláez A; Prat A
Lancet Oncol; 2017 Apr; 18(4):545-554. PubMed ID: 28238593
[TBL] [Abstract][Full Text] [Related]
15. Response and survival of breast cancer intrinsic subtypes following multi-agent neoadjuvant chemotherapy.
Prat A; Fan C; Fernández A; Hoadley KA; Martinello R; Vidal M; Viladot M; Pineda E; Arance A; Muñoz M; Paré L; Cheang MC; Adamo B; Perou CM
BMC Med; 2015 Dec; 13():303. PubMed ID: 26684470
[TBL] [Abstract][Full Text] [Related]
16. BRCA Mutation-Related and Claudin-Low Breast Cancer: Blood Relatives or Stepsisters.
Madaras L; Balint N; Gyorffy B; Tokes AM; Barshack I; Yosepovich A; Friedman E; Paluch-Shimon S; Zippel D; Baghy K; Timar J; Kovalszky I; Kulka J; Szasz AM
Pathobiology; 2016; 83(1):1-12. PubMed ID: 26566278
[TBL] [Abstract][Full Text] [Related]
17. High
Onaga C; Tamori S; Motomura H; Ozaki A; Matsuda C; Matsuoka I; Fujita T; Nozaki Y; Hara Y; Kawano Y; Harada Y; Sato T; Mano Y; Sato K; Akimoto K
Anticancer Res; 2021 Jan; 41(1):43-54. PubMed ID: 33419798
[TBL] [Abstract][Full Text] [Related]
18. EpCAM based capture detects and recovers circulating tumor cells from all subtypes of breast cancer except claudin-low.
Ring A; Mineyev N; Zhu W; Park E; Lomas C; Punj V; Yu M; Barrak D; Forte V; Porras T; Tripathy D; Lang JE
Oncotarget; 2015 Dec; 6(42):44623-34. PubMed ID: 26556851
[TBL] [Abstract][Full Text] [Related]
19. [Is there a claudin-low phenotype of breast cancer?].
Popova OP; Kuznetsova AV; Bogomazova SY; Ivanov AA
Arkh Patol; 2022; 84(1):45-49. PubMed ID: 35166478
[TBL] [Abstract][Full Text] [Related]
20. Cancer stem cell-driven efficacy of trastuzumab (Herceptin): towards a reclassification of clinically HER2-positive breast carcinomas.
Martin-Castillo B; Lopez-Bonet E; Cuyàs E; Viñas G; Pernas S; Dorca J; Menendez JA
Oncotarget; 2015 Oct; 6(32):32317-38. PubMed ID: 26474458
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
